{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pityriasis-rosea/management/management/","result":{"pageContext":{"chapter":{"id":"0bc06d9c-42f1-5228-adf5-4eda9826e67a","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 3a66cec2-f711-46a7-b574-7bbeafb9c784 --><h2>Scenario: Management</h2><!-- end field 3a66cec2-f711-46a7-b574-7bbeafb9c784 -->","summary":"Covers the primary care management of pityriasis rosea.","htmlStringContent":"<!-- begin item 8d021edf-d30c-44ca-848c-ec1f9bc4e537 --><!-- begin field 3979f17e-79df-4ea6-b037-acbc0159b16e --><p>From age 1 month onwards.</p><!-- end field 3979f17e-79df-4ea6-b037-acbc0159b16e --><!-- end item 8d021edf-d30c-44ca-848c-ec1f9bc4e537 -->","topic":{"id":"c96d68c3-bb0b-5b8c-b256-6b3e415d7ab2","topicId":"76763692-46bc-4f1e-add3-6c012ccd584a","topicName":"Pityriasis rosea","slug":"pityriasis-rosea","lastRevised":"Last revised in April 2020","chapters":[{"id":"82c04d82-7b6f-594a-8190-44f70c341f1b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b21af5b-81ad-5b28-9df9-d6b7c4fdd3d4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"357337fc-eefc-5ff8-84bf-cc4e15f9a2da","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67565f4b-e371-5339-8d04-8fb65cb26c28","slug":"changes","fullItemName":"Changes"},{"id":"3b3d1372-8e27-5563-9a36-273677bd9a82","slug":"update","fullItemName":"Update"}]},{"id":"75f5c2f6-34b3-5b64-ab41-c7457b8eedd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"26135976-eb67-5dd8-ad15-9a98086871b7","slug":"goals","fullItemName":"Goals"},{"id":"96f6df37-1ba4-5020-8435-cbeac8de1488","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"026de696-4951-5e10-a246-456d67c1fea8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"03d26d2a-90f8-53c5-97e9-cff9d95ae299","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87a8200e-6cd0-588d-8d4b-86117be364e6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ba1ef82b-8a8a-558d-a84a-552083dcd2e1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a8f04415-38ec-5eb9-8282-733c37db5bac","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"38f858f2-48f8-54e6-bb01-5b58106435cc","slug":"definition","fullItemName":"Definition"},{"id":"f7fffe58-e2a4-5913-8a5a-354aad8d52f0","slug":"causes","fullItemName":"Causes"},{"id":"090f1bfe-2513-53a8-ade3-e8368ec7d5d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"20025f23-bbb9-5095-9acc-da8d9e15840b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"72d63a33-0ca6-552f-81a8-200eef91d046","slug":"complications","fullItemName":"Complications"}]},{"id":"75dd0d1f-b162-54b6-b1ba-3833b13ae73e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"44c5742e-2d6e-5ce6-806a-03940c5572f8","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f2c8da26-1065-5bb2-add8-43b39f41b5fe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d71093b6-b130-5eeb-8e0f-443adf8be4aa","fullItemName":"Management","slug":"management","subChapters":[{"id":"0bc06d9c-42f1-5228-adf5-4eda9826e67a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c48f4302-0f7c-58d9-86ad-d5379d244e71","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"eee3f004-1425-502e-a455-287742b3ec77","slug":"emollients","fullItemName":"Emollients"},{"id":"51eb73bd-9e63-5028-815d-bf148fa863d9","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"186fab77-8c30-557b-bd7b-f756eb8f9cab","slug":"antihistamines","fullItemName":"Antihistamines"}]},{"id":"b3c2db78-1290-58fb-9bb3-3a5db8e45669","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e683b047-2b38-5f72-a4b8-c79a83946894","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2d6d1b8c-ffc1-59d1-89f5-a5abdf200635","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27361c81-c185-5b67-b396-0305d0519609","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45051d9e-ec60-5c2c-b5ba-3144fa01ed3b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4e570021-eea5-51d7-a0b9-52d2862efb98","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"259f8083-da67-544d-b6f7-dbb776d27e96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4c25a2fe-3c87-5ac4-b4c3-7f8e41ff3c06","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d71093b6-b130-5eeb-8e0f-443adf8be4aa","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"b2d76a38-523c-5fd8-9213-18bb9cd81d32","slug":"management-in-primary-care","fullItemName":"Management in primary care","depth":3,"htmlHeader":"<!-- begin field 119afcd5-d22f-42e2-bef7-0b1aae70e740 --><h3>How should I manage a person with pityriasis rosea?</h3><!-- end field 119afcd5-d22f-42e2-bef7-0b1aae70e740 -->","summary":null,"htmlStringContent":"<!-- begin item 81d426f8-d6ac-44c3-8154-92812869b020 --><!-- begin field 96c8a4ea-3e40-46d6-a543-ac6ebc8dccfc --><ul><li><strong>If pityriasis rosea develops in pregnancy</strong> — discuss management urgently with secondary care.</li><li><strong>For most people with pityriasis rosea, no specific treatment is required.</strong><ul><li>Explain that the rash may worsen before it resolves, with new crops of skin lesions continuing to appear for up to 6 weeks.</li><li>Reassure the person that:<ul><li>The rash will settle without treatment, usually within 2–3 months.</li><li>No treatment is required apart from symptomatic treatment for itch.</li><li>After the rash has disappeared, there may be some hyperpigmentation or hypopigmentation of the affected skin for several months, but there will be no scarring.</li><li>The rash does not usually recur: about 1 in every 50 people with pityriasis rosea may have a recurrence.</li></ul></li><li>Offer further information such as the patient information leaflet <a href=\"http://www.bad.org.uk/library-media/documents/Pityriasis%20rosea%20Update%20Nov%202014%20-%20lay%20reviewed%20Aug%202014(2).pdf\" data-hyperlink-id=\"1fde0f01-f161-4637-b4be-ab7d00b3f370\">Pityriasis rosea</a> available on the wBritish Association of Dermatologists website (<a href=\"http://www.bad.org.uk/\" data-hyperlink-id=\"80acdef9-cd6b-48ce-9f81-ab7a00dbc179\">http://www.bad.org.uk</a>).</li></ul></li><li><strong>For people with itch, consider offering symptomatic treatment with one or more of the following: </strong><ul><li>An emollient — for information on prescribing emollients see the <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/\">Emollients</a> section in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a>.</li><li>A mildly-potent topical corticosteroid (such as hydrocortisone 1%) or moderately-potent topical corticosteroid (such as betamethasone valerate 0.025% or clobetasone 0.05%) ointment or cream applied once or twice daily for up to 4 weeks — choice of potency depends on severity of itch.<ul><li>For information on prescribing topical corticosteroids, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a>.</li></ul></li><li>An oral antihistamine (off-label) —  consider a sedating oral antihistamine (for example chlorphenamine) given at night if itching affects sleep. If there is no relief of itch after 2 weeks of treatment, the antihistamine should be discontinued.<ul><li>For more information on antihistamines, including contraindications and cautions, see the <a class=\"topic-reference external-reference\" href=\"/topics/itch-widespread/prescribing-information/\">Prescribing</a> section in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/itch-widespread/\">Itch - widespread</a>.</li></ul></li></ul></li><li><strong>If itch is severe </strong>(for example it is not relieved by moderately-potent topical corticosteroids), reconsider the diagnosis — do <em>not</em> prescribe an oral corticosteroid.</li><li><strong>Refer to a dermatology specialist if: </strong><ul><li>The diagnosis is uncertain.</li><li>An atypical form of pityriasis rosea is suspected.</li><li>The person has extensive disease, or severe itch not controlled by simple treatments in primary care.</li></ul></li></ul><!-- end field 96c8a4ea-3e40-46d6-a543-ac6ebc8dccfc --><!-- end item 81d426f8-d6ac-44c3-8154-92812869b020 -->","subChapters":[{"id":"73bed65c-50cd-59fa-89be-1780b9be4f05","slug":"basis-for-recommendation-b60","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ff365f50-0e4e-4f1b-aa5f-02294e14217d --><h4>Basis for recommendation</h4><!-- end field ff365f50-0e4e-4f1b-aa5f-02294e14217d -->","summary":null,"htmlStringContent":"<!-- begin item b60142b6-4bb5-4d61-8e21-7a3f34b7b095 --><!-- begin field 4f829b19-13c9-4bf5-ac5b-c1fa5787eb74 --><h5>Pityriasis rosea in pregnancy</h5><ul><li>Pityriasis rosea in the first 15 weeks of pregnancy has been associated with adverse outcomes including miscarriage, premature delivery, and neonatal hypotonia. Secondary care may consider further investigation and antiviral treatment — urgent discussion/referral is indicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Drago, 2018</a>].</li></ul><h5>Explanation and reassurance</h5><ul><li>These recommendations are based on expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">PCDS, 2018</a>], a position statement from the European Academy of Dermatology and Venereology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh, 2016</a>], a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>], and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Villalon-Gomez, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Contreras‐Ruiz, 2019</a>].</li></ul><h5>Emollients for symptom relief</h5><ul><li>The recommendation on use of an emollient if the rash is itchy is based on expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">PCDS, 2018</a>], a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>], and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Trayes, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Contreras‐Ruiz, 2019</a>].</li><li>Emollients form a film on the skin surface, which helps retain moisture in the stratum corneum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Penzer, 2012</a>]; this softens the skin, reduces cracking and dryness, prevents itching, and helps to remove scales.</li></ul><h5>Topical corticosteroids for symptom relief</h5><ul><li>The recommendation on use of topical corticosteroids to alleviate itch is based on expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">PCDS, 2018</a>], a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>], and review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Villalon-Gomez, 2018</a>].</li><li>In the absence of evidence on potency, frequency of application, or duration of treatment, these recommendations are based on expert opinion from previous external reviewers of this CKS topic.</li></ul><h5>Oral antihistamines for symptom relief</h5><ul><li>The recommendation on use of oral antihistamines for pityriasis rosea is based on a position statement from the European Academy of Dermatology and Venereology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh, 2016</a>], expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>], and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Trayes, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Villalon-Gomez, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">BMJ Best Practice, 2019</a>]. This recommendation is also extrapolated from expert opinion of previous external reviewers of the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/itch-widespread/\">Itch - widespread</a>.</li><li>A Cochrane review of interventions for pityriasis rosea found inadequate evidence on whether oral antihistamines provide any clinical benefit compared with no treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Contreras‐Ruiz, 2019</a>].</li></ul><h5>Treatments not recommended in primary care</h5><ul><li>Oral corticosteroids are usually reserved for a severe rash and itch that has not been controlled with topical treatments or oral antihistamines — specialist input is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Zawar et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Villalon-Gomez, 2018</a>].</li></ul><h5>When to refer</h5><ul><li>Recommendations on when to refer a person with pityriasis rosea are based on a position statement from the European Academy of Dermatology and Venereology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh, 2016</a>], expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>], and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Drago et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Eisman and Sinclair, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Drago, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Trayes, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Villalon-Gomez, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Rebora, 2019</a>].</li><li>If diagnosis is uncertain or presentation atypical biopsy may be indicated to confirm diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Trayes, 2018</a>].</li><li>Although high-quality evidence for treatments such as acyclovir (off-label) or phototherapy in pityriasis rosea is lacking, these may be considered in secondary care for cases that are severe or refractory to treatment in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Eisman and Sinclair, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Sterling, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Trayes, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Villalon-Gomez, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Contreras‐Ruiz, 2019</a>].</li></ul><!-- end field 4f829b19-13c9-4bf5-ac5b-c1fa5787eb74 --><!-- end item b60142b6-4bb5-4d61-8e21-7a3f34b7b095 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}